Nanosphere, Inc. (NASDAQ:NSPH) , a company enhancing medicine through targeted molecular diagnostics, announced the closing of its previously announced registered direct offering of …
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that a 20-to-1 reverse split of its common stock will be effective …
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, and Scripps Health, a private, nonprofit, integrated health system in San Diego, California, today announced …
In a research report sent to investors, Roth Capital analyst Chris Lewis reiterated a Buy rating on Nanosphere (NASDAQ:NSPH), but reduced the price …
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report preliminary results for the fourth quarter …
In a research note published Monday, Canaccord analyst Mark Massaro reiterated a Buy rating on Nanosphere (NASDAQ:NSPH) with a $3 price target, in …
In a research report published today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Nanosphere (NASDAQ:NSPH) with a $1.50 price target, as NSPH …
In a research note released yesterday, Roth Capital analyst Chris Lewis reaffirmed a Buy rating on Nanosphere (NSPH) with a $3 price target …
In a research report released today, Canaccord analyst Mark Massaro reiterated coverage with a “Buy” rating on Nanosphere, Inc. (NSPH) and a price target of $5.
Nanosphere, Inc. (NSPH) announced this morning that it received FDA clearance for the bacterial portion of its enteric pathogen (EP) test.
